

CANADIAN GUIDELINES ON SEXUALLY TRANSMITTED INFECTIONS (2008 UPDATE)

V – MANAGEMENT AND TREATMENT OF SPECIFIC INFECTIONS

CHANCROID (January 2008)

References

1. Hammond GW, Slutchuk M, Scatliff J, Sherman E, Wilt JC, Ronald AR. Epidemiologic, clinical, and laboratory therapeutic features of an urban outbreak of chancroid in North America. *Rev Infect Dis* 1980;2:867–879.
2. Steen R. Eradicating chancroid. *Bull World Health Organ* 2001;79:818–826.
3. Cameron DW, Simonsen JN, D'Costa LJ, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. *Lancet* 1989;2:403–407.
4. Spinola SM, Bauer ME, Munson RS Jr. Immunopathogenesis of *Haemophilus ducreyi* infection (chancroid). *Infect Immun* 2002;70:1667–1676.
5. Trees DL, Morse SA. Chancroid and *Haemophilus ducreyi*: an update. *Clin Microbiol Rev* 1995;8:357–375.
6. Malonza IM, Tyndall MW, Ndinya-Achola JO, et al. A randomized, double-blind, placebo-controlled trial of single-dose ciprofloxacin versus erythromycin for the treatment of chancroid in Nairobi, Kenya. *J Infect Dis* 1999;180:1886–1893.
7. Roest RW, van der Meijden WI; European Branch of the International Union against Sexually Transmitted Infection and the European Office of the World Health Organization. European guideline for the management of tropical genito-ulcerative diseases. *Int J STD AIDS* 2001;12(suppl 3):78–83.
8. Tyndall MW, Agoki E, Plummer FA, Malisa W, Ndinya-Achola JO, Ronald AR. Single dose azithromycin for the treatment of chancroid: a randomized comparison with erythromycin. *Sex Transm Dis* 1994;21:231–234.
9. Martin DH, Sargent SJ, Wendel GD Jr, McCormack WM, Spier NA, Johnson RB. Comparison of azithromycin and ceftriaxone for the treatment of chancroid. *Clin Infect Dis* 1995;21:409–414.
10. Tyndall M, Malisa M, Plummer FA, Ombetti J, Ndinya-Achola JO, Ronald AR. Ceftriaxone no longer predictably cures chancroid in Kenya. *J Infect Dis* 1993;167:469–471.